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ABSTRACT
Over the last decade, genome-wide association
studies (GWAS) have become the standard tool for
gene discovery in human disease research. While
debate continues about how to get the most out of
these studies and on occasion about how much
value these studies really provide, it is clear that
many of the strongest results have come from
large-scale mega-consortia and/or meta-analyses
that combine data from up to dozens of studies
and tens of thousands of subjects. While such
analyses are becoming more and more common,
statistical methods have lagged somewhat behind.
There are good meta-analysis methods available,
but even when they are carefully and optimally
applied there remain some unresolved statistical
issues. This article systematically reviews the
GWAS meta-analysis literature, highlighting meth-
odology and software options and reviewing
methods that have been used in real studies. We
illustrate differences among methods using a case
study. We also discuss some of the unresolved
issues and potential future directions.
INTRODUCTION
Genome-wide Association Studies (GWAS) test for stat-
istical association between genotype and phenotype on
hundreds of thousands to millions of single nucleotide
polymorphisms (SNPs) at a time in order to ﬁnd genes
that contribute to human diseases or non-disease traits.
Early in the GWAS era, costs were high and sample
sizes were small, but with technological advances prices
have come down signiﬁcantly and typical sample sizes
are now in the thousands. Even with those large sample
sizes, discoveries have been modest for many or most
phenotypes studied because typical effect sizes are quite
small, and many results do not appear to replicate in sub-
sequent studies. As a result, most GWAS publications
now involve multiple data sets in order to both reduce
false positives and increase statistical power to ﬁnd true
positives. Often these multiple data sets are analyzed indi-
vidually, or some of them are only used for ‘in-silico rep-
lication’ (i.e. only top markers from one data set are
examined in the remaining data sets). There is growing
recognition, however, that the most statistically robust
and efﬁcient analysis is a full-genome meta-analysis
combining all studies and using all data at every marker.
Meta-analysis provides optimum power to ﬁnd effects that
are homogeneous across cohorts, and at the same time can
shed light on between-study heterogeneity (1–5). Going
even further, many investigators are now forming
mega-consortia of a dozen or more studies for increased
statistical power. Meta-analysis thus has become a routine
part of GWAS, and yet there remain unresolved issues
about the most powerful and robust ways to use it. This
article attempts to provide a comprehensive review of
GWAS meta-analysis methods, practices and problems,
with the goal of helping both applied and methodological
researchers take the necessary next steps forward. In the
next section we provide an overview of GWAS
meta-analysis methods, and in ‘Databases and software’
we review databases and software. ‘Literature review’
summarizes the methods used in the literature, and
‘Case study’ presents our case study. Finally, in
‘Complications and open questions’ we discuss important
open questions.
GWAS META-ANALYSIS DATA AND METHODS
It is fairly common for an individual investigator to
perform GWAS on several different study populations
and combine the results into a single report. If the
genotyping is done for all studies together, data from
the different populations can be directly combined
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sary. GWAS investigators generally turn to meta-analysis
when scans are performed on different chips and/or when
results from different investigators need to be combined
and raw data cannot be exchanged for reasons of either
conﬁdentiality or proprietorship.
There has historically been some concern about the ap-
propriateness of mega-analysis and even meta-analysis
given the high level of heterogeneity among GWAS of
the same trait. Sources of heterogeneity between studies
can include different trait measurements and study
designs, different ethnic groups, different environmental
exposures, different genotyping chips, etc. For example,
if two study populations have signiﬁcantly different envir-
onmental backgrounds (say different diets in an obesity
study), different genes may be relevant to the trait in the
two populations (i.e. there may be gene environment
interaction). Another important source of heterogeneity
is differing linkage disequilibrium patterns in different
ethnic groups, so that even if the same variant is causal
in both groups, the SNPs that are associated (in linkage
disequilibrium) with it may differ from group to group.
Recently, Lin et al. allayed some of these concerns. They
showed both theoretically and by simulation that
meta-analysis and mega-analysis have essentially equal
statistical efﬁciency, and also that the efﬁciency of both
approaches is fairly robust to between-study heterogeneity
(6). Heterogeneity remains a concern, however, and we
will discuss it further throughout the article (e.g. in the
random effects model, case study and open questions).
Most GWAS meta-analysis uses relatively straightfor-
ward methods. P-values can be combined either with or
without weights, or effect sizes can be combined in either
ﬁxed or random effects models. (See the companion paper
on microarray meta-analysis for a more detailed expos-
ition of the differences among these methods). Any of
those methods can be applied either across all studies at
once, or cumulatively as each study is added. Most GWAS
meta-analysis takes a frequentist approach, but Bayesian
hierarchical models can also be used, and are very
well-suited to a cumulative approach (7). Table 1 lists
the commonly-used GWAS meta-analysis methods and
the source information that is required for each. The
methods are described in a bit more detail below.
The simplest GWAS meta-analysis approach is to
combine P-values using Fisher’s method. The formula
for the statistic is
X2 ¼  2
X k
i¼1
logðpiÞ
where pi is the P-value for the ith study. Under the null
hypothesis, X
2 follows a chi-squared distribution with 2k
degrees of freedom, where k is the number of studies. A
major limitation of this method is that all studies are
weighted equally, which is likely to be highly suboptimal
when combining GWAS studies with different sample
sizes. An additional problem is that the direction of
effect of each SNP is not considered, so that studies
with associations in opposite directions appear to
strengthen each other rather than contradicting each
other.
A major improvement over Fisher’s method is a
weighted Z-score method, in which P-values are trans-
formed to Z-scores in a one-to-one transformation. The
weighted Z-score method is more powerful and efﬁcient
than Fisher’s method, and allows different weights for dif-
ferent studies (8). It also takes into account the direction
of the effect at each SNP. The software METAL (9) im-
plements the weighted Z-score method using the following
formula:
Z ¼
 i ziwi ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
 iw2
i
p ,
where the weight wi=square root of sample size of the ith
study, Zi ¼   1ð1  
pi
2Þ ð effectdirectionforstudyiÞ, and
pi is the P-value for the ith study. Note that the
METAL paper has a typo in this formula but we have
conﬁrmed by testing the software that the formula
shown above is in fact correctly implemented in the
software.
The major alternative to combining P-values and/or
Z-scores is to combine effect sizes (estimates). This can
be done with either a ﬁxed effects or a random effects
model. Combining effect sizes is statistically more
powerful than combining Z-scores, but it requires that
the trait be measured on exactly the same scale in each
study, with the same units, same transformations, etc. This
may be achievable in a meta-analysis of a trait with highly
standardized measurements, but there are many traits for
which it is unlikely to be possible, for example alcohol or
tobacco use. The difference between the ﬁxed effects and
random effects models is that ﬁxed effects meta-analysis
assumes that the genetic effects are the same across the
different studies. Fixed effects models provide narrower
conﬁdence intervals and signiﬁcantly lower P-values for
the variants than random effects models (1,10–14). Both
ﬁxed effects and random effects models are brieﬂy dis-
cussed below; details can be found in Nakaoka et al.
(2009) (15).
For the ﬁxed effects model, inverse-variance weighting
is widely used, although other methods are also available.
The weighted average of the effect sizes can be calculated
as ^  F ¼ð  iwi ^  iÞ=ð iwiÞ and the variance of the weighted
average of the effect size is varð^  FÞ¼1=
P
iwi
  
, where ^  i is
the logarithm of the ith case-control study effect, wi is the
Table 1. Sources of information for different methods of
meta-analysis
Fisher’s, P Weighted Z Fixed
effect
Random
effect
P-value X X
Effect size X X
Direction of the
effect size
X
Sample size X
Heterogeneity estimate X
SE of effect size X X
3778 Nucleic Acids Research, 2012,Vol.40, No. 9reciprocal of the estimated variance of the effect size for
the ith case-control study.
The random effects model assumes that the mean
effect (of each SNP) in each study is different, with
those means usually assumed to be chosen from a
Gaussian distribution. The variance of that Gaussian dis-
tribution, and thus the amount of between-study hetero-
geneity, is estimated by the model. Thus the random
effects model not only does not assume homogeneity
of effect but is able to give an estimate of the degree of
heterogeneity. The weight of each study incorporates
the between-study variance of heterogeneity, which is
expressed as  2, where
 2 ¼ Q  ð k   1Þ ðÞ =  iwi  
 iw2
i
 iwi
     
:
The weight for the random effects model is calculated
as wR
i ¼ 1=ð 1
wi+^  2Þ and Q ¼  iwiðb  i    FÞ
2, Cochran’s test
statistic (16) follows a chi-squared distribution with k 1
degrees of freedom under the assumption of genetic homo-
geneity. Q is most widely used to check the between-study
heterogeneity. But Q is underpowered when the number of
studies is small. To overcome this problem, there are some
other statistics available, such as H, R and I
2, deﬁned as
H ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Q=ðk   1Þ
p
, R ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
varð^  RÞ=varð^  FÞ
q
and
I2 ¼ 100  ð Q  ð K   1ÞÞ=Q, where ^  R is the genetic effect
under the random effects model. H, R and I
2 have some
desirable characteristics such as being scale and size in-
variant (10,15). These statistics are calculated separately
for each SNP, which leads to the interesting and unsolved
question of whether or how one should make a
genome-wide determination of heterogeneity.
In addition to these basic methods, almost any
meta-analysis method in the statistical literature can be
applied to GWAS, and some of the software packages
discussed below do so.
DATABASES AND SOFTWARE
Most GWAS meta-analyses are assembled from consortia
of investigators working on similar traits, but public data-
bases are also used. The most important GWAS database
is the NIH Database of Genotype and Phenotype
(dbGaP), which is the repository for both raw data and
results from most NIH-funded GWAS. There are also a
number of databases that contain selected results from
GWAS studies, some of which are suitable for inclusion
in meta-analyses of targeted regions. GWAS Central is
one of the oldest such databases, which started in 1998
under a different name. On 27 April 2011, it contained 708
studies. The Human Genome Epidemiology Network
(HuGE Net) (http://www.hugenet.ca) also has a GWAS
integrator webpage and contains a list of publications,
hits, variants, disease and trait information etc. Like
HuGE Net, The National Human Genome Research
Institute (NHGRI) (http://www.genome.gov/gwastudies)
maintains a catalog of published GWAS studies (17).
Other available databases include the HKSC database
with both bone mineral density (BMD) and fracture
data (18) and the Millennium Genome Project (MGP)
(https://gemdbj.nibio.go.jp/dgdb/), which has a repository
of Japanese SNP(JSNP) data (19).
The statistical methods used for GWAS meta-analysis
are very straightforward, and it is not difﬁcult to imple-
ment them, but there are several software packages avail-
able that can make this easier and that integrate useful
bioinformatics or visualization functions. The most
widely used software is METAL (http://genome.sph
.umich.edu/wiki/METAL_Program) (9). METAL imple-
ments two strategies, a weighted Z-score method based
on sample size, P-value and direction of effect in each
study, and an effect-size based method weighted by the
study-speciﬁc standard error. The other most commonly
used package is MetABEL, which is a component of the
GenABEL suite in R. MetABEL implements a ﬁxed effects
model like METAL, and results can be shown with a visu-
alization tool. A number of other packages are also in use,
including META (http://www.stats.ox.ac.uk/ jsliu/meta
.html). GWAMA (20) has useful auxiliary features that
METAL, MetABEL, and META lack. PLINK (http://
pngu.mgh.harvard.edu/ purcell/plink/metaanal.shtml)
(21) is a free, open-source software for GWAS analysis,
which also has some meta-analysis tools to do ﬁxed
effects and random effects meta-analysis. MAGENTA
(http://www.broadinstitute.org/mpg/magenta/) (22) can
be used to test a speciﬁc hypothesis or to generate
hypotheses, and it provides gene set enrichment analysis
P-values and false discovery rate. Comprehensive Meta-
analysis (CMA) (www.Meta-Analysis.com) Software (23)
is a commercial package to do meta-analysis which
works in a spreadsheet interface and also provides forest
plots, which are useful for visualizing between-study het-
erogeneity (see case study). Review Manager (RevMan)
(http://ims.cochrane.org/revman/about-revman-5) (24) is
another package that does meta-analysis and provides
results in tabular format and graphically. It also provides
different kinds of reviews including intervention reviews,
diagnostic test accuracy reviews, methodology reviews and
overviews of the reviews. There are several STATA
modules to perform meta-analysis, such as METAN (25),
HETEROGI (25) and more speciﬁcally METAGEN (26)
(http://bioinformatics.biol.uoa.gr/ pbagos/metagen) for
genetic association studies. In R, a few other available
packages for meta-analysis are Metafor (http://www
.metafor-project.org/) (27), rmeta, and CATMAP. The
Metafor package has different functions to calculate
ﬁxed, random and mixed effects along with moderator
and meta-regression analysis and provides different kinds
of graphical displays of results and data. Synthesis-view
(https://chgr.mc.vanderbilt.edu/synthesisview) (28) is a
visualization tool which can integrate multiple pieces of
information across studies, such as P-values, effect sizes,
allele frequencies etc. IGG3 (29) can integrate raw GWAS
data from multiple chips and provide the input ﬁles for
different imputation software, which can be used in
meta-analysis later. Magi and Morris (2010) made a nice
comparison of different features among a number of
meta-analysis software packages (20).
Nucleic Acids Research,2012, Vol.40, No. 9 3779One issue that is unique to GWAS meta-analysis is that
SNPs may not be coded the same way in different data
sets—the so-called ‘strand’ issue. Opposite coding of SNPs
in different studies can cause what should be similar
effects to look precisely opposite. This often occurs for
only a small subset of SNPs (those with minor allele
frequencies  50%) and so can be very difﬁcult to detect.
Most of the meta-analysis software packages discussed
above have varying bioinformatics features to resolve
this problem, including METAL, MetABEL, META
and GWAMA (20).
LITERATURE REVIEW
This review started with a search of GWAS meta-analysis
using PubMed on 29 December 2010, which yielded 299
papers. After removing duplicates and irrelevant papers
there were 249 GWAS meta-analysis papers (see
complete searching and paper collection criteria in the
companion paper). Figure 1 summarizes the number of
papers by year of publication, illustrating the exponential
increase between 2005 and 2010. Figure 2 summarizes the
contents of the papers. One hundred and eighty-seven
papers (75%) are full GWAS meta-analyses, while 58
papers (23%) are replication analyses on targeted loci
(Figure 2A). Figure 2B shows that the majority of
reports are biological applications (226 papers; 91%)
while 10 papers (4%) are for novel methodology, 4
papers (1%) are databases and software, and 9 papers
(4%) are review papers.
Figure 2C and 2D show the methods and software used.
One hundred and sixty-four papers (80%) use ﬁxed or
random effects models, 28 (14%) combine weighted Z-
scores from P-values, 6 (3%) use Fisher’s method, and 7
(3%) use direct data merging. For software packages,
METAL (41 papers; 45%) and R packages (23 papers;
25%) are the most popular. Other software choices
include PLINK (six papers; 7%); GWAMA (three
papers; 3%); and GenABEL/MetABEL (ﬁve papers;
5%). Detailed information of the paper list and categor-
ization to generate Figure 2 is available in the online
Supplementary Data.
CASE STUDY
In this section, we present a simple case study that dem-
onstrates some of the differences among GWAS
Figure 2. Summary of GWAS meta-analysis review: (A) type of meta-analysis; (B) type of paper; (C) type of meta-analysis method;
(D) software used.
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Figure 1. Number of GWAS studies by year of publication. Command
used in PubMed search: [‘meta-analysis’(Title/Abstract)] AND
[‘genome-wide association’(Title/Abstract)].
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meta-analysis, which we label here as data set 1 and data
set 2. The data sets are from different studies and different
populations, but both were genotyped on the Illumina
Human660-Quad Beadchip. The phenotype is total
meiotic recombination across the genome, which has
been of great interest in the genetics literature lately,
with many new discoveries especially about the ‘recombin-
ation hotspot gene’ PRDM9. Meiotic recombination
events for both parents in nuclear families were scored
according to Chowdhury et al. (30) The gene RNF212 is
well-known to be associated with recombination (30–32),
so we report results for four SNPs within this gene.
Because the reported associations between RNF212 and
recombination differ in males and females, we consider
males and females both separately and combined in our
case study, which provides an illustration of how the dif-
ferent meta-analysis methods behave in the presence of
heterogeneity. All the methods of meta-analysis for our
case study were implemented by us in R.
Table 2 shows the results of our case study. The ﬁrst
four rows give the single-study P-values for each SNP in
the four data sets (data set 1 male, data set 1 female, data
set 2 male, data set 2 female). These are based on standard
GWAS methods using linear regression for each SNP
under an additive genetic model. No multiple comparisons
correction was applied. The notable result is that all
P-values are highly signiﬁcant in the data set 1 males,
but not in either set of females. In the data set 2 males,
two of the SNPs have P-values of 0.01 and two are on the
order of 0.20. Note that the sample size in data set 2 is
much smaller than in data set 1, so even if the effects
are the same in the two data sets we would expect larger
P-values in data set 2.
When the four meta-analysis methods are used to
combine the two male data sets for the ﬁrst two SNPs,
they all perform reasonably well, but there are clear dif-
ferences. Fisher’s method has the lowest power (highest
P-values), as would be expected because it is using equal
weights for these two very different-sized sets. The highest
power is found with both the ﬁxed and random effects
models; the similarity of these two methods for these
two SNPs indicates that the ﬁxed effects model ﬁts well.
For the third and fourth SNPs, the weighted Z-score
method and the ﬁxed effects model have better power
than Fisher’s method. The random effects model estimates
a very large random component and gives a very high
P-value for the SNP. This is probably an artifact caused
by ﬁtting a random effects model to just two data sets.
Based on the biology, a ﬁxed effects model is likely to be
more or less correct for this phenotype, as long as only a
single sex is included in the analysis.
In combining the female data sets, all four meta-analysis
methods also behave similarly, reﬂecting the lack of sig-
niﬁcant association.
When all four data sets (males and females) are
combined, we can clearly see the effect of the heterogen-
eity on the different meta-analysis methods. In general the
ﬁxed effects model retains good power to detect associ-
ation despite our inclusion of some studies (the females)
that have little or no effect, while the random effects
model completely loses power because it is ﬁtting an in-
correct model of a Gaussian random effect. That is, our
male and female effects are not the same, but they are not
random either—what we actually have is a mixture of two
ﬁxed—effects models. We suggest that the typical situ-
ation in a GWAS meta-analysis is likely to be similar to
this—a mixture of ﬁxed effects rather than a true random
effect—and thus that the random effects model may not
be the most appropriate way to deal with heterogeneity in
GWAS meta-analysis. This proposition clearly deserves
further study, however.
One important way to visualize heterogeneity is with a
forest plot, which shows the separate estimates and their
conﬁdence intervals for each study, and also shows the
combination. Figure 3 is a forest plot for all four SNPs
and all four populations in the case study; the overall
effect shown in the forest plots is from the ﬁxed-effects
model. The R package ‘rmeta’ was used to generate the
forest plots. These plots make it very easy to visualize
some of the important features that the P-values only
hint at, such as the fact that the two male populations
are in fact quite consistent with each other despite the
differing P-values, and the fact that the female effect is
actually in the opposite direction (which is consistent
with the recombination literature).
COMPLICATIONS AND OPEN QUESTIONS
GWAS meta-analysis is now widely used and in general
has worked well to discover genetic effects that were not
uncovered in individual studies. There are, however, some
remaining barriers and open methodological issues.
Table 2. Case study results
SNPs in RNF212
rs3796619 rs4974601 rs2045065 rs12645644
Study analysis
Data set 1, P-value
Male (n=736) 1.4E 6 1.4E 6 1.7E 6 1.8E 6
Female (n=736) 0.76 0.76 0.19 0.25
Data set 2, P-value
Male (n=174) 0.01 0.01 0.23 0.21
Female (n=174) 0.15 0.14 0.82 0.82
Meta-analysis
Fisher, P-value
Male 2.7E 7 2.7E 7 6.2E 6 5.9E 6
Female 0.36 0.35 0.45 0.52
Combined 2.6E 6 2.5E 6 5.7E 5 6.7E 5
Weighted Z, P-value
Male 2.35E 8 2.35E 8 6.87E 7 6.34E 7
Female 0.36 0.36 0.10 0.13
Combined 1.97E 5 1.91E 5 5.96E 3 4.46E 3
Fixed effect, P-value
Male 1.7E 8 1.7E 8 7.0E 7 6.3E 7
Female 0.35 0.35 0.10 0.12
Combined 2.3E 7 2.2E 7 1.6E 4 1.1E 4
Random effect, P-value
Male 1.7E 8 1.7E 8 1.7E 1 1.5E 1
Female 0.34 0.34 0.10 0.12
Combined 3.0E 1 3.0E 1 4.5E 1 4.4E 1
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Prior to meta-analysis, it is clearly important that all data
sets undergo thorough standard GWAS data cleaning,
such as ﬁltering out ‘bad’ SNPs and samples using
genotype call rates, tests of Hardy–Weinberg equilibrium
(HWE), etc (33). What is not entirely clear is how import-
ant it is that the data cleaning steps and standards be the
same across data sets. For example, can it cause problems
if different genotype call rate cutoffs are used in different
data sets? This has not been systematically studied to our
knowledge. In genetic association studies for targeted
SNPs, there have been three ways to deal with HWE:
including all studies irrespective of the HWE tests (34),
doing sensitivity analysis to verify differential genetic
effects in subgroups (15,35–37), and excluding studies
with statistically signiﬁcant deviation from HWE(15,38).
More recently, most large consortium meta-analyses have
attempted to use consistent HWE cutoffs across studies,
which is clearly the safest approach.
It is also not clear whether it is necessary or desirable to
implement data cleaning steps that compare data sets to
each other. The same SNP assay can behave differently on
different chips, or even on the same chip in different
batches, and thus it is common to scan data sets for
SNPs with widely differing allele frequencies and eliminate
them before combining. But if the data sets are from dif-
ferent ethnic groups, there will also be SNPs for which
there are ‘true’ differences in allele frequency. It is not
clear whether there is a way to distinguish the artifacts
from the real differences, and thus it is difﬁcult to recom-
mend an ideal cleaning strategy. Similarly, HWE testing
poses issues when data sets are combined (as discussed
above), but it is probably clear that HWE tests on
combined data sets would be unacceptably conservative.
These issues are particularly important in the situation
where different studies have different phenotype distribu-
tions (or, equivalently, different case:control ratios).
Imputation
When studies are genotyped on different chips, there may
be very little overlap in the SNP sets, and thus direct
SNP-by-SNP meta-analysis is impossible. For example,
the overlap between the Illumina 550K SNP set and the
Affymetrix 500K SNP set is only about 100K or 20% of
SNPs. The standard solution to this problem is to impute
the genotypes of all SNPs in all samples, and a variety of
good methods is available for doing so (39). The problem
this creates, which has not been carefully addressed in the
literature, is that imputed genotypes have slightly higher
error rates and variances than non-imputed genotypes. In
general, if imputation is done carefully, the error rates are
very low. Error rates can be higher, however, for areas of
the genome with sparse SNP coverage or for ethnic groups
that are not well represented in the data set that is used for
Figure 3. Forest plot of the selected SNPs.
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As with data cleaning above, this issue can be critical if
different studies have different phenotype distributions. If
two studies have different case:control ratios and one is
genotyped and one imputed for a particular SNP, then
there is a resulting difference between case and control
variances, which can cause false positive results.
Conversely, if one chip has very poor coverage of a
region, then imputation will create ‘genotypes’ that
actually convey very little information, in which case the
meta-analysis can give false negative results because it is
averaging in non-informative data sets. Some kind of
regionally-smoothed meta-analysis may be the solution
to this problem, but such methods have not been de-
veloped to our knowledge. In general, it is always advis-
able to check data quality of replicate results that are
based predominantly on imputed data.
Choice of genetic models
In GWAS analysis, the basic association test can be based
on an allele frequency comparison or on various statistical
contrasts of genotype frequencies, for example an additive
model, a dominant model, etc. The same model is used for
each SNP, so usually something relatively robust such as
the additive model is used (40). It is most desirable in
meta-analysis to use the same model in each study, but
in post hoc combinations of analyses that might not always
be possible. To our knowledge, no one has studied the
effect of such variation in association model on
meta-analysis. Clearly it causes some level of effect het-
erogeneity that would, at least formally, violate a ﬁxed
effects model, though it would not ﬁt a Gaussian
random effects model either. Similar issues arise if differ-
ent covariates or different methods for controlling for
population stratiﬁcation are used in different studies.
Between-study heterogeneity
As discussed above, between-study heterogeneity should
probably be considered the norm in GWAS meta-analysis.
Such heterogeneity is important to discover and report,
since it can lead to important biological insights, for
example differences in the genetic control of male and
female recombination. The conventional wisdom in the
statistical literature is that when heterogeneity is present
or even likely, the random effects model is more appro-
priate than the ﬁxed effects model. We suggest that this
might not be the right approach for GWAS, because
(i) the number of studies being combined is often not
very large (leading to an imprecise heterogeneity
estimate) and (ii) the form of the heterogeneity typically
does not ﬁt a Gaussian random effects model. We do
suggest that forest plots are an important heuristic
method for discovering and understanding heterogeneity,
but we also propose that further work on random or
mixed-effects models that are a better ﬁt to GWAS data
might improve analyses. For example, in our recombin-
ation example we know that males and females are likely
to be different, so we could ﬁt a model that explicitly has
different ﬁxed male and female effects.
CONCLUSION
As the GWAS literature moves away from artiﬁcial ‘rep-
lication’ and toward the more statistically optimal direct
combination of all available data in a meta-analysis
framework, it will be critical for investigators to under-
stand the best methods for performing that meta-analysis.
While good methods are already in use in most studies,
there is room for improvement in many of the details dis-
cussed above. Many of the potential improvements are
ideally addressed by planning studies in a coordinated
manner from the beginning, but that is not always
feasible. We still need improved methods for post hoc com-
binations of studies that may have signiﬁcant heterogen-
eity in chip, study population, environmental exposures,
association tests, etc. Looking even further ahead, all of
the issues addressed above will need to be re-examined for
meta-analyses of SNP data derived from sequencing
studies, which will undoubtedly be appearing soon in
journals throughout the ﬁeld.
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